These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3403261)

  • 21. Topical preparations and their use in dermatology.
    Wohlrab J
    J Dtsch Dermatol Ges; 2016 Nov; 14(11):1061-1070. PubMed ID: 27879084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The selection of skin care products for use in hyperbaric chamber may depend on flammability acceptability indices score.
    McCord DE; Newton BE; Fore J; Chiffoleau G
    Adv Skin Wound Care; 2008 Feb; 21(2):79-84. PubMed ID: 18349735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cosmeceuticals: undefined, unclassified, and unregulated.
    Draelos ZD
    Clin Dermatol; 2009; 27(5):431-4. PubMed ID: 19695473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanostructured novel carrier for topical application.
    Guglielmini G
    Clin Dermatol; 2008; 26(4):341-6. PubMed ID: 18691513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Topical therapy--risks and unwanted effects].
    Zesch A
    Z Hautkr; 1986 Jun; 61(11):821-3. PubMed ID: 3739399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of innovative cosmeceuticals.
    Gao XH; Zhang L; Wei H; Chen HD
    Clin Dermatol; 2008; 26(4):367-74. PubMed ID: 18691517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical screening program for topical chemotherapeutic drugs in psoriasis.
    Weinstein GD; McCullough JL; Eaglstein WH; Golub A; Cornell RC; Stoughton RB; Clendenning W; Zackheim H; Maibach H; Kulp KR; King L; Baden HP; Taylor JS; Deneau DD
    Arch Dermatol; 1981 Jul; 117(7):388-93. PubMed ID: 6789777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Influence of excipients on glucocorticoid determination in dermatological preparations].
    Halot D; Lanson M
    Ann Pharm Fr; 1971 Nov; 29(11):533-9. PubMed ID: 5138616
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial.
    Khemis A; Kaiafa A; Queille-Roussel C; Duteil L; Ortonne JP
    Br J Dermatol; 2007 May; 156(5):997-1004. PubMed ID: 17388924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Local and transcutaneous pharmacotherapy. Pharmacokinetic principles and clinical evaluation].
    Stüttgen G; Täuber U; Bauer E; Zesch A
    Hautarzt; 1986 Feb; 37(2):65-76. PubMed ID: 3957664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The importance of vehicles in the dermatological therapy].
    Tronnier H
    Z Haut Geschlechtskr; 1969 Mar; 44(5):155-68. PubMed ID: 5360173
    [No Abstract]   [Full Text] [Related]  

  • 32. [Topical corticosteroids in dermatology--advantages and side effects].
    Wojas-Pelc A; Setkowicz M; Bogdaszewska-Czabanowska J
    Przegl Lek; 2002; 59(3):170-4. PubMed ID: 12184032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The generics in transplantation and the rules on their use.
    Masri M
    Exp Clin Transplant; 2003 Jun; 1(1):65-8. PubMed ID: 15859910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Final report on the safety assessment of Cocoyl Sarcosine, Lauroyl Sarcosine, Myristoyl Sarcosine, Oleoyl Sarcosine, Stearoyl Sarcosine, Sodium Cocoyl Sarcosinate, Sodium Lauroyl Sarcosinate, Sodium Myristoyl Sarcosinate, Ammonium Cocoyl Sarcosinate, and Ammonium Lauroyl Sarcosinate.
    Lanigan RS
    Int J Toxicol; 2001; 20 Suppl 1():1-14. PubMed ID: 11358107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-inflammatory ingredients.
    Wu J
    J Drugs Dermatol; 2008 Jul; 7(7 Suppl):s13-6. PubMed ID: 18681154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue distribution and kinetics of endogenous porphyrins synthesized after topical application of ALA in different vehicles.
    Casas A; Fukuda H; Batlle AM
    Br J Cancer; 1999 Sep; 81(1):13-8. PubMed ID: 10487606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revocation of Office of Generic Drug's interim policy statement on inactive ingredients. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Apr; 64(83):23340-1. PubMed ID: 10558498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multivesicular emulsion: a novel, controlled-release delivery system for topical dermatological agents.
    Bikowski J; Shroot B
    J Drugs Dermatol; 2006; 5(10):942-6. PubMed ID: 17373142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moisturizers for the treatment of inflammatory skin conditions.
    Lynde C
    J Drugs Dermatol; 2008 Nov; 7(11):1038-43. PubMed ID: 19110734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.